IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) - Total Liabilities
Based on the latest financial reports, IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) has total liabilities worth €2.60 Billion EUR (≈ $3.04 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore IPSEN SA SP.ADR 1/4/ EO 1 (I7G0) equity growth momentum to track the company's year-over-year net asset growth rate.
IPSEN SA SP.ADR 1/4/ EO 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how IPSEN SA SP.ADR 1/4/ EO 1's total liabilities have evolved over time, based on quarterly financial data.
IPSEN SA SP.ADR 1/4/ EO 1 Competitors by Total Liabilities
The table below lists competitors of IPSEN SA SP.ADR 1/4/ EO 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GD Power Development Co Ltd
SHG:600795
|
China | CN¥381.37 Billion |
|
Fidelity National Financial Inc
NYSE:FNF
|
USA | $101.08 Billion |
|
Dycom Industries Inc
NYSE:DY
|
USA | $4.12 Billion |
|
Unum Group
NYSE:UNM
|
USA | $51.82 Billion |
|
RPM International Inc
NYSE:RPM
|
USA | $4.74 Billion |
|
Mapfre
MC:MAP
|
Spain | €48.00 Billion |
|
Anhui Jianghuai Automobile Group Corp Ltd
SHG:600418
|
China | CN¥37.31 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down IPSEN SA SP.ADR 1/4/ EO 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of IPSEN SA SP.ADR 1/4/ EO 1.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IPSEN SA SP.ADR 1/4/ EO 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IPSEN SA SP.ADR 1/4/ EO 1 (2021–2025)
The table below shows the annual total liabilities of IPSEN SA SP.ADR 1/4/ EO 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €2.60 Billion ≈ $3.04 Billion |
+15.23% |
| 2024-12-31 | €2.26 Billion ≈ $2.64 Billion |
-9.68% |
| 2023-12-31 | €2.50 Billion ≈ $2.92 Billion |
+10.03% |
| 2022-12-31 | €2.27 Billion ≈ $2.66 Billion |
+0.82% |
| 2021-12-31 | €2.25 Billion ≈ $2.63 Billion |
-- |
About IPSEN SA SP.ADR 1/4/ EO 1
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more